FDA CGM Data Submission: Tracing Sensor Epochs to the Final Analysis Dataset
How FDA's May 2026 CGM technical specifications link SDTM LB epochs, ADCGM phantom rows and ADCGMEN completeness variables, and what the SAP must lock first.

The journal
Independent analysis of endpoint strategy, measurement operations, and clinical trial systems.
How FDA's May 2026 CGM technical specifications link SDTM LB epochs, ADCGM phantom rows and ADCGMEN completeness variables, and what the SAP must lock first.

When competing events occur, choosing between cumulative incidence and cause-specific hazard depends on the probability question and ICH E9(R1) estimand strategy.

How clinical trial teams structure imaging charters to handle reader disagreement, unreadable series, and missing scans before database lock.

How clinical trial teams choose wearable non-wear rules, define valid days, and distinguish missing observations from intercurrent events.

Which endpoint data must be reconciled and evidenced before a clinical database lock, who signs each row, and how unlock and unblinding stay controlled.

Decide which PRO questionnaires a clinical trial needs by mapping objectives, checking combined burden, and justifying timing in a hypothetical worked example.

How to write ClinicalTrials.gov outcome measures from the protocol endpoint, which 42 CFR 11.64 update clock applies after an amendment, and what results QC checks.

What to record when a trial visit falls outside its protocol window, how to classify the deviation, and when the SAP analysis window still counts the endpoint.

Why daily diary averages and 7-day recall scores for the same PRO items diverge, what FDA guidance says about changing a recall period, and what to lock before the eCOA build.

How trial teams timestamp a withdrawal boundary, keep endpoint data already collected in an FDA-regulated database, and stop only the collection the participant has refused.

How data management teams query an endpoint discrepancy without supplying the answer, and what to do when the site confirms the original value.

How clinical trial teams should specify caregiver eligibility, unique credentials, audit trails, and transition sensitivity analyses when diary respondents change.
